Compare J M Smucker Co (SJM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs Travere Therapeutics Inc. Common Stock — how do they compare? J M Smucker Co trades at $122 (market cap $12.96B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: J M Smucker Co is far larger — about 2.7× Travere Therapeutics Inc. Common Stock's market cap, and J M Smucker Co pays a 3.69% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold J M Smucker Co for 74 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SJM | TVTX | |
|---|---|---|
Market Cap | $12.96B | $4.88B |
Volume | 1,039,289 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $132.34 | $67.52 |
52-Week Low | $89.53 | $26.79 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $19.81B | $5.01B |
Dividend Yield | 3.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $121.84, up 1.52% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $3.24, beating expectations, and raised FY27 guidance. However, 2025 fundamentals show a net loss of $1.23B and elevated P/E of 56.7, while analyst consensus is a Buy with a $138.23 price target.
Outlook is mixed; robust growth in segments like Uncrustables and raised guidance support upside, but high valuation, volatile profitability, and debt levels pose risks. The stock offers a dividend yield but faces competitive and margin pressures in the consumer staples sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
